March 2024. MSB meets with FDA regarding potency data.
March 2024. MSB says they have feedback from FDA, and
"U.S. FDA has informed the company that following additional consideration the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application (BLA) for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD)."
So the assay prevented the study from being adequate. MSB provided more assay data and had a meeting with FDA about assays. Now the FDA says the study appears sufficient to support resubmission.
Could it be that FDA's review of the new assay data has led them to look more favorably upon the study?
Just connecting dots.
MSB Price at posting:
$1.08 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)